University Hospitals Seidman Cancer Center

Seidman Cancer Center at UH Case Medical

Cleveland, OH

Not yet accepting

KarMMa-9

Phase 3 Clinical Trial Comparing the Efficacy and Safety of Idecabtagene Vicleucel with Lenalidomide Maintenance to Approved Lenalidomide Maintenance Alone in Patients with Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Stem Cell Transplant
Learn more
  • CAR T Cell
  • Immunomodulatory Drug
  • BCMA
  • Randomization
  • Phase 3

Not yet accepting

MonumenTAL-3

Phase 3 Clinical Trial Comparing the Efficacy of an Investigational Medication Combined with Daratumumab or Daratumumab and Pomalidomide Versus Daratumumab, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma.
Learn more
  • Bispecific Antibody
  • GPRC5D
  • Randomization
  • Phase 3
All clinical trials have eligibility criteria - or a list of reasons why you may be able or unable to participate in a trial. Answer a few questions to view your personalized results - all in under 60 seconds.
Help me find trials

Accepting patients

Treatment Experience of Patients

Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia (AML) Using Remote Symptom Monitoring
Learn more

Not yet accepting

IDP-023

Phase 1/2 Study of IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
Learn more
  • Natural Killer Cells (Allogeneic)
  • Phase 1/2

Not currently accepting

DRAMMATIC

S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration (DRAMMATIC)
Learn more
  • Monoclonal Antibody
  • CD38
  • Maintenance
  • Phase 3

Accepting patients

Investigational Cord Blood Units

Safety Study of Unlicensed, Investigational Cord Blood Units Manufactured by the National Cord Blood Program (NCBP) for Unrelated Transplantation
Learn more
  • Allogeneic Stem Cell Transplant
  • Phase 2

Accepting patients

LMY-920

LMY-920 for Treatment of Relapsed or Refractory Myeloma (LMY-920-002)
Learn more
  • CAR T Cell
  • BAFF
  • Phase 1